Related Experiment Video
Updated: Jun 5, 2026

NF-κB-dependent Luciferase Activation and Quantification of Gene Expression in Salmonella Infected Tissue Culture Cells
Published on: January 12, 2020
NF-κB, inflammation, and metabolic disease
Rebecca G Baker1, Matthew S Hayden, Sankar Ghosh
1Department of Microbiology and Immunology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.
Chronic low-grade inflammation, not just lipid storage, drives metabolic diseases like obesity and diabetes. The transcription factor NF-κB is a key player, offering new therapeutic targets.
Area of Science:
- Biochemistry
- Immunology
- Metabolic Science
Background:
- Metabolic disorders like obesity, type 2 diabetes, and atherosclerosis were historically considered solely lipid storage issues due to overnutrition.
- Emerging evidence highlights chronic low-grade inflammation as a critical factor in the onset and progression of these metabolic diseases.
Purpose of the Study:
- To investigate the role of inflammation and the transcription factor NF-κB in metabolic disease development.
- To establish inflammation as a critical etiological factor in metabolic disorders.
Main Methods:
- Review of recent studies implicating NF-κB in metabolic disease.
- Analysis of the role of NF-κB in coordinating inflammatory responses.
Main Results:
- NF-κB is significantly implicated in the development of metabolic diseases.
- Inflammation is confirmed as a critical factor in the etiology of metabolic disorders.
Conclusions:
- Inflammation, mediated by factors like NF-κB, is central to metabolic disease development.
- Targeting inflammatory pathways, particularly NF-κB, presents promising therapeutic strategies for metabolic disorders.
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
NF-kB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Inflammatory Bowel Disease III: Crohn's Disease
Chronic Inflammation: Introduction
Inflammatory Bowel Disease II: Ulcerative Colitis
Co-activators and Co-repressors

